08 Mar 2024: T-DXd (Enhertu) exhibits intracranial activity in HER2+ breast cancer brain metastases meta-analysis
Investigators observed no significant differences in ORR and IC-ORR between the clinical trials and observational studies included in this meta-analysis
T-DXd is suggested as a second-line treatment for HER2-positive breast cancer with stable and active brain metastases.
info@ciscientists.com
For a subscription, please provide your email id